(Q35908298)

11 August 2017

1 reference

title

Nutrition in patients with cystic fibrosis: a European Consensus (English)

1 reference

11 August 2017

0 references

M Sinaasappel

1

1 reference

11 August 2017

M Stern

2

1 reference

11 August 2017

J Littlewood

3

1 reference

11 August 2017

S Wolfe

4

1 reference

11 August 2017

G Steinkamp

5

1 reference

11 August 2017

Harry G M Heijerman

6

1 reference

11 August 2017

E Robberecht

7

1 reference

11 August 2017

G Döring

8

1 reference

11 August 2017

language of work or name

1 reference

1 June 2002

1 reference

Journal of Cystic Fibrosis

11 August 2017

published in

1 reference

11 August 2017

volume

1

1 reference

11 August 2017

issue

2

1 reference

11 August 2017

page(s)

51-75

1 reference

Wasting as an independent predictor of mortality in patients with cystic fibrosis

11 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2802%2900032-2

7 January 2021

Growth of human milk-fed and formula-fed infants with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2802%2900032-2

7 January 2021

Disproportionate head growth retardation in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2802%2900032-2

7 January 2021

Early diagnosis of cystic fibrosis through neonatal screening prevents severe malnutrition and improves long-term growth. Wisconsin Cystic Fibrosis Neonatal Screening Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2802%2900032-2

7 January 2021

A comparison of survival, growth, and pulmonary function in patients with cystic fibrosis in Boston and Toronto

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2802%2900032-2

7 January 2021

Linear growth in children with cystic fibrosis. I. Birth to 8 years of age

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2802%2900032-2

7 January 2021

Clinical outcomes of newborn screening for cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2802%2900032-2

7 January 2021

Growth status in children with cystic fibrosis based on the National Cystic Fibrosis Patient Registry data: evaluation of various criteria used to identify malnutrition

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2802%2900032-2

7 January 2021

Body mass index reference curves for the UK, 1990

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2802%2900032-2

7 January 2021

Height and weight in cystic fibrosis: a cross sectional study. UK Cystic Fibrosis Survey Management Committee

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2802%2900032-2

7 January 2021

Delayed puberty in girls with cystic fibrosis despite good clinical status

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2802%2900032-2

7 January 2021

The adolescent growth spurt in children with cystic fibrosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2802%2900032-2

7 January 2021

Nutritional assessment and management in cystic fibrosis: a consensus report. The Consensus Committee

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2802%2900032-2

7 January 2021

Reliability of percentage ideal weight for height

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2802%2900032-2

7 January 2021

Clinical longitudinal standards for height, weight, height velocity, weight velocity, and stages of puberty

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2802%2900032-2

7 January 2021

Cross sectional stature and weight reference curves for the UK, 1990.

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2802%2900032-2

7 January 2021

Euro-Growth references for body mass index and weight for length. Euro-Growth Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2802%2900032-2

7 January 2021

Establishing a standard definition for child overweight and obesity worldwide: international survey

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2802%2900032-2

7 January 2021

Body fat assessed from body density and estimated from skinfold thickness in normal children and children with cystic fibrosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2802%2900032-2

7 January 2021

Body composition of adult cystic fibrosis patients and control subjects as determined by densitometry, bioelectrical impedance, total-body electrical conductivity, skinfold measurements, and deuterium oxide dilution

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2802%2900032-2

7 January 2021

Total Body Potassium in Cystic Fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2802%2900032-2

7 January 2021

Evaluation of growth and changes in body composition following neonatal diagnosis of cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2802%2900032-2

7 January 2021

Use of bioelectrical impedance analysis to measure total body water in patients with cystic fibrosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2802%2900032-2

7 January 2021

Assessment of whole-body composition with dual-energy x-ray absorptiometry

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2802%2900032-2

7 January 2021

Bone density in children and adolescents with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2802%2900032-2

7 January 2021

Low bone mineral density in adults with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2802%2900032-2

7 January 2021

Short stature in a patient with cystic fibrosis caused by a 6.7-kb human growth hormone gene deletion

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2802%2900032-2

7 January 2021

Asthma treatment and growth

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2802%2900032-2

7 January 2021

Pseudo-Bartter's syndrome in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2802%2900032-2

7 January 2021

Pancreatic insufficiency, growth, and nutrition in infants identified by newborn screening as having cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2802%2900032-2

7 January 2021

Longitudinal evaluation of serum trypsinogen measurement in pancreatic-insufficient and pancreatic-sufficient patients with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2802%2900032-2

7 January 2021

Increased intragastric acid-resistant lipase activity and lipolysis in pancreatic steatorrhoea due to cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2802%2900032-2

7 January 2021

Carbohydrate malabsorption is minimal in school-age cystic fibrosis children

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2802%2900032-2

7 January 2021

Duodenal pH in cystic fibrosis and its relationship to fat malabsorption

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2802%2900032-2

7 January 2021

Effect of intrajejunal acidity on aqueous phase bile acid and lipid concentrations in pancreatic steatorrhoea due to cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2802%2900032-2

7 January 2021

Faecal bile acid and dietary residue excretion in cystic fibrosis: age group variations.

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2802%2900032-2

7 January 2021

Abnormal biliary lipid composition in cystic fibrosis. Effect of pancreatic enzymes

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2802%2900032-2

7 January 2021

Fat malabsorption in cystic fibrosis patients receiving enzyme replacement therapy is due to impaired intestinal uptake of long-chain fatty acids

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2802%2900032-2

7 January 2021

Small intestinal permeability and orocaecal transit time in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2802%2900032-2

7 January 2021

Use of pancreatic enzyme supplements for patients with cystic fibrosis in the context of fibrosing colonopathy. Consensus Committee

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2802%2900032-2

7 January 2021

Markers for faecal fat estimation in monitoring steatorrhoea in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2802%2900032-2

7 January 2021

Clinical monitoring of steatorrhoea in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2802%2900032-2

7 January 2021

Clinical use of acid steatocrit

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2802%2900032-2

7 January 2021

Faecal chymotrypsin: a reliable index of exocrine pancreatic function

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2802%2900032-2

7 January 2021

Sensitivity and specificity of quantitative determination of pancreatic elastase 1 in feces of children

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2802%2900032-2

7 January 2021

Evaluation of fecal pancreatic elastase-1 as a measure of pancreatic exocrine function in children with cystic fibrosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2802%2900032-2

7 January 2021

13Carbon mixed triglyceride breath test and pancreatic enzyme supplementation in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2802%2900032-2

7 January 2021

Validation in an animal model of the carbon 13-labeled mixed triglyceride breath test for the detection of intestinal fat malabsorption

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2802%2900032-2

7 January 2021

Comparison of the diagnostic value of serum pancreatic isoamylase and immunoreactive trypsin measurement in patients with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2802%2900032-2

7 January 2021

Adequacy of clinical formulae for estimation of energy requirements in children with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2802%2900032-2

7 January 2021

Measured versus predicted resting energy expenditure in infants: a need for reappraisal.

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2802%2900032-2

7 January 2021

Resting energy expenditure and oxygen cost of breathing in patients with cystic fibrosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2802%2900032-2

7 January 2021

Effect of elective antibiotic therapy on resting energy expenditure and inflammation in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2802%2900032-2

7 January 2021

Acute pulmonary exacerbation is not associated with increased energy expenditure in children with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2802%2900032-2

7 January 2021

Resting energy expenditure before and after treatment for Pseudomonas aeruginosa infection in patients with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2802%2900032-2

7 January 2021

Metabolic and inflammatory responses to pulmonary exacerbation in adults with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2802%2900032-2

7 January 2021

Plasma interleukin-1 alpha and beta, tumor necrosis factor-alpha, and lipopolysaccharide concentrations during pulmonary exacerbations of cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2802%2900032-2

7 January 2021

Effects of administration of aerosolized recombinant human deoxyribonuclease on resting energy expenditure in patients with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2802%2900032-2

7 January 2021

Total energy expenditure in stable patients with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2802%2900032-2

7 January 2021

Increased energy expenditure in cystic fibrosis is associated with specific mutations

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2802%2900032-2

7 January 2021

Prospective evaluation of resting energy expenditure, nutritional status, pulmonary function, and genotype in children with cystic fibrosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2802%2900032-2

7 January 2021

Resting energy expenditure, pulmonary inflammation, and genotype in the early course of cystic fibrosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2802%2900032-2

7 January 2021

The cystic fibrosis gene and resting energy expenditure

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2802%2900032-2

7 January 2021

Energy expenditure and genotype of children with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2802%2900032-2

7 January 2021

Effect of salbutamol on resting energy expenditure in patients with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2802%2900032-2

7 January 2021

Discrepancies between males and females with cystic fibrosis in dietary intake and pancreatic enzyme use.

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2802%2900032-2

7 January 2021

Randomized, double-blind, placebo-controlled pilot trial of megestrol acetate in malnourished children with cystic fibrosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2802%2900032-2

7 January 2021

Growth hormone improves clinical status in prepubertal children with cystic fibrosis: results of a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2802%2900032-2

7 January 2021

Liver involvement in cystic fibrosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2802%2900032-2

7 January 2021

Natural history of liver disease in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2802%2900032-2

7 January 2021

Recommendations for management of liver and biliary tract disease in cystic fibrosis. Cystic Fibrosis Foundation Hepatobiliary Disease Consensus Group

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2802%2900032-2

7 January 2021

Liver disease does not affect lipolysis as measured with the 13C-mixed triacylglycerol breath test in children with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2802%2900032-2

7 January 2021

Effects of ursodeoxycholic acid treatment on nutrition and liver function in patients with cystic fibrosis and longstanding cholestasis

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2802%2900032-2

7 January 2021

Effect of a Medium Dose of Ursodeoxycholic Acid with or without Taurine Supplementation on the Nutritional Status of Patients with Cystic Fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2802%2900032-2

7 January 2021

Glucose tolerance in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2802%2900032-2

7 January 2021

Diagnosis, screening and management of cystic fibrosis related diabetes mellitus: a consensus conference report

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2802%2900032-2

7 January 2021

Relation between defective regulation of arachidonic acid release and symptoms in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2802%2900032-2

7 January 2021

Relation between essential fatty acid metabolism and gastrointestinal symptoms in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2802%2900032-2

7 January 2021

Essential fatty acid deficiency in relation to genotype in patients with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2802%2900032-2

7 January 2021

A membrane lipid imbalance plays a role in the phenotypic expression of cystic fibrosis in cftr(-/-) mice

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2802%2900032-2

7 January 2021

Energy supplements rich in linoleic acid improve body weight and essential fatty acid status of cystic fibrosis patients

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2802%2900032-2

7 January 2021

Essential fatty acid deficiency affects the fatty acid composition of the rat small intestinal and colonic mucosa differently

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2802%2900032-2

7 January 2021

Essential fatty acid deficiency in well nourished young cystic fibrosis patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2802%2900032-2

7 January 2021

Pathological regulation of arachidonic acid release in cystic fibrosis: the putative basic defect

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2802%2900032-2

7 January 2021

Ursodeoxycholic acid improves the hepatic metabolism of essential fatty acids and retinol in children with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2802%2900032-2

7 January 2021

Deficiency of vitamins E and A in cystic fibrosis is independent of pancreatic function and current enzyme and vitamin supplementation

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2802%2900032-2

7 January 2021

Depressed plasma Vitamin A and retinol-binding protein in cystic fibrosis correlations with zinc deficiency

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2802%2900032-2

7 January 2021

Vitamin A concentration in the liver decreases with age in patients with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2802%2900032-2

7 January 2021

Vitamin A deficiency and nocturnal vision in teenagers with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2802%2900032-2

7 January 2021

Xerophthalmia and cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2802%2900032-2

7 January 2021

Prospective, long-term study of fat-soluble vitamin status in children with cystic fibrosis identified by newborn screen

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2802%2900032-2

7 January 2021

Serum concentrations of vitamin D-binding protein (group-specific component) in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2802%2900032-2

7 January 2021

Bone mineral content and body composition in children and young adults with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2802%2900032-2

7 January 2021

Bone mass and vitamin D deficiency in adults with advanced cystic fibrosis lung disease

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2802%2900032-2

7 January 2021

Pulmonary dysfunction in cystic fibrosis is associated with oxidative stress

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2802%2900032-2

7 January 2021

Short-term changes in erythrocyte alpha-tocopherol content of vitamin E-deficient patients with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2802%2900032-2

7 January 2021

[Taurine supplementation in cystic fibrosis (CF): effect on vitamin E absorption kinetics]

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2802%2900032-2

7 January 2021

Malabsorption of vitamin E in cystic fibrosis improved after ursodeoxycholic acid

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2802%2900032-2

7 January 2021

Impaired resistance to oxidation of low density lipoprotein in cystic fibrosis: improvement during vitamin E supplementation

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2802%2900032-2

7 January 2021

Anaemia, vitamin E deficiency and failure to thrive in an infant

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2802%2900032-2

7 January 2021

Symptomatic vitamin E deficiency in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2802%2900032-2

7 January 2021

Impaired brainstem auditory evoked potentials in patients with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2802%2900032-2

7 January 2021

Effect of vitamin K1 supplementation on vitamin K status in cystic fibrosis patients

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2802%2900032-2

7 January 2021

Treatment of vitamin K deficiency in cystic fibrosis: Effectiveness of a daily fat-soluble vitamin combination

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2802%2900032-2

7 January 2021

Malabsorption of vitamin B12 in pancreatic insufficiency of the adult and of the child

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2802%2900032-2

7 January 2021

Plasma vitamin C concentrations in patients with cystic fibrosis: evidence of associations with lung inflammation.

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2802%2900032-2

7 January 2021

Sodium space and intravascular volume: dietary sodium effects in cystic fibrosis and healthy adolescent subjects

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2802%2900032-2

7 January 2021

Bone mineral status in 134 patients with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2802%2900032-2

7 January 2021

Bone mineral content in cystic fibrosis patients: correlation with fat-free mass

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2802%2900032-2

7 January 2021

Bone histomorphometry in adult patients with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2802%2900032-2

7 January 2021

Altered calcium homeostasis in adults with cystic fibrosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2802%2900032-2

7 January 2021

Low plasma zinc concentrations in young infants with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2802%2900032-2

7 January 2021

Effect of pancreatic enzymes on zinc absorption in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2802%2900032-2

7 January 2021

Reduced copper enzyme activities in blood cells of children with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2802%2900032-2

7 January 2021

Altered antioxidant status and increased lipid peroxidation in children with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2802%2900032-2

7 January 2021

Effects of pancreatic enzyme preparations on erythrocyte glutathione peroxidase activities and plasma selenium concentrations in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2802%2900032-2

7 January 2021

Plasma chromium concentrations in normal infants and cystic fibrosis patients

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2802%2900032-2

7 January 2021

Systemic deficiency of glutathione in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2802%2900032-2

7 January 2021

Lymphocyte glutathione levels in children with cystic fibrosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2802%2900032-2

7 January 2021

Enhanced resistance to oxidation of low density lipoproteins and decreased lipid peroxide formation during beta-carotene supplementation in cystic fibrosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2802%2900032-2

7 January 2021

Supplementation with carotenoids corrects increased lipid peroxidation in children with cystic fibrosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2802%2900032-2

7 January 2021

Neutrophil elastase/alpha 1-proteinase inhibitor complex levels decrease in plasma of cystic fibrosis patients during long-term oral beta-carotene supplementation

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2802%2900032-2

7 January 2021

Fat gram target to achieve high energy intake in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2802%2900032-2

7 January 2021

Dietary fibre and the occurrence of gut symptoms in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2802%2900032-2

7 January 2021

Do infants with cystic fibrosis need a protein hydrolysate formula? A prospective, randomized, comparative study

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2802%2900032-2

7 January 2021

Cows' milk sensitive enteropathy in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2802%2900032-2

7 January 2021

Nutritional impact of antipseudomonas intravenous antibiotic courses in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2802%2900032-2

7 January 2021

Energy balance during acute respiratory exacerbations in children with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2802%2900032-2

7 January 2021

Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus.

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2802%2900032-2

7 January 2021

Effectiveness and safety of small vs. large doses of enteric coated pancreatic enzymes in reducing steatorrhea in children with cystic fibrosis: a prospective randomized study

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2802%2900032-2

7 January 2021

Comparison of weight-based dosages of enteric-coated microtablet enzyme preparations in patients with cystic fibrosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2802%2900032-2

7 January 2021

A double blind lipase for lipase comparison of a high lipase and standard pancreatic enzyme preparation in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2802%2900032-2

7 January 2021

Uses and abuses of enzyme therapy in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2802%2900032-2

7 January 2021

https://api.crossref.org/works/10.1016%2FS1569-1993%2802%2900032-2

1 reference

7 January 2021

Pancreatic enzyme replacement therapy in cystic fibrosis: Australian guidelines. Pediatric Gastroenterological Society and the Dietitians Association of Australia

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2802%2900032-2

7 January 2021

Update on intestinal strictures.

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2802%2900032-2

7 January 2021

New insights on gastro-oesophageal reflux in cystic fibrosis by longitudinal follow up

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2802%2900032-2

7 January 2021

Gastro-oesophageal reflux in infants under 6 months with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2802%2900032-2

7 January 2021

Liver and biliary problems in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2802%2900032-2

7 January 2021

Desensitization to pancreatic enzyme intolerance in a child with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2802%2900032-2

7 January 2021

Comparative study of varying regimens to improve steatorrhoea and creatorrhoea in cystic fibrosis: Effectiveness of an enteric-coated preparation with and without antacids and cimetidine

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2802%2900032-2

7 January 2021

Improvement of fecal fat excretion after addition of omeprazole to pancrease in cystic fibrosis is related to residual exocrine function of the pancreas.

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2802%2900032-2

7 January 2021

Taurine decreases fecal fatty acid and sterol excretion in cystic fibrosis. A randomized double-blind trial

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2802%2900032-2

7 January 2021

Serum immunoglobulin G directed against porcine trypsin in pancreatic insufficient cystic fibrosis patients receiving pancreatic enzyme supplements

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2802%2900032-2

7 January 2021

Is fibrosing colonopathy an immune mediated disease?

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2802%2900032-2

7 January 2021

Allergy in cystic fibrosis nurses to pancreatic extract

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2802%2900032-2

7 January 2021

Hypersensitivity to pancreatic extracts in parents of patients with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2802%2900032-2

7 January 2021

Strictures of ascending colon in cystic fibrosis and high-strength pancreatic enzymes

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2802%2900032-2

7 January 2021

Fibrosing colonopathy in cystic fibrosis: results of a case-control study

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2802%2900032-2

7 January 2021

High-dose pancreatic-enzyme supplements and fibrosing colonopathy in children with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2802%2900032-2

7 January 2021

Colonic strictures in children with cystic fibrosis on low-strength pancreatic enzymes

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2802%2900032-2

7 January 2021

Colonic wall thickness, pancreatic enzyme dose and type of preparation in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2802%2900032-2

7 January 2021

Colonic toxicity from pancreatins: a contemporary safety issue

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2802%2900032-2

7 January 2021

Pancreatic enzymes and fibrosing colonopathy

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2802%2900032-2

7 January 2021

Colonic wall thickness and pancreatic enzymes in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2802%2900032-2

7 January 2021

Effect of linoleic acid intake on growth of infants with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2802%2900032-2

7 January 2021

Correction of linoleic acid deficiency in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2802%2900032-2

7 January 2021

Erythrocyte Sodium-Potassium Transport in Cystic Fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2802%2900032-2

7 January 2021

Omega-3 fatty acids suppress the enhanced production of 5-lipoxygenase products from polymorph neutrophil granulocytes in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2802%2900032-2

7 January 2021

The absorption and effect of dietary supplementation with omega-3 fatty acids on serum leukotriene B4 in patients with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2802%2900032-2

7 January 2021

Eicosapentaenoic acid in cystic fibrosis: evidence of a pathogenetic role for leukotriene B4

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2802%2900032-2

7 January 2021

The use of an intravenous fish oil emulsion enriched with omega-3 fatty acids in patients with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2802%2900032-2

7 January 2021

Improvement of nutritional status and lung function after long-term nocturnal gastrostomy feedings in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2802%2900032-2

7 January 2021

Pulmonary function correlates in the prediction of long-term weight gain in cystic fibrosis patients with gastrostomy tube feedings

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2802%2900032-2

7 January 2021

Nutrition intervention for weight gain in cystic fibrosis: a meta analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2802%2900032-2

7 January 2021

Improved exercise tolerance with long-term parenteral nutrition in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2802%2900032-2

7 January 2021

Percutaneous sonographic gastrostomy: method, indications, and problems

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2802%2900032-2

7 January 2021

Percutaneous endoscopic gastrostomy feeding in patients with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2802%2900032-2

7 January 2021

Nutritional effects of long-term gastrostomy feedings in children with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2802%2900032-2

7 January 2021

Enteral nutrition for patients with cystic fibrosis: comparison of a semi-elemental and nonelemental formula

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2802%2900032-2

7 January 2021

Prolonged parenteral nutrition for cystic fibrosis patients

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2802%2900032-2

7 January 2021

Energy needs and nutritional rehabilitation in undernourished adolescents and young adult patients with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2802%2900032-2

7 January 2021

The effect of a comprehensive, intensive inpatient treatment program on lung function and exercise capacity in patients with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2802%2900032-2

7 January 2021

Oxygen-assisted exercise training in adult cystic fibrosis patients with pulmonary limitation to exercise

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2802%2900032-2

7 January 2021

10.1016/S1569-1993(02)00032-2

Identifiers

DOI

1 reference

11 August 2017

1 reference